All Stories

  1. Graves’ orbitopathy following Alemtuzumab treatment for multiple sclerosis: a systematic review and real-world insights
  2. Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy
  3. Impact of thyroid disorders on flow-mediated dilation: a systematic review and meta-analysis
  4. Process to radioactive iodine treatment for Graves’ hyperthyroidism: condemned or absolved?
  5. Natural Killer Cells in Graves’ Disease: Increased Frequency but Impaired Degranulation Ability Compared to Healthy Controls
  6. Nutritional Approach in Thyroid Disease: Reality and Myths to Dispel
  7. Assessment of the Correlation between Unipolar and Bipolar Depression, Calcium Levels, Thyroid Function, and Inflammatory Markers: A Pilot Prospective Study
  8. Autoimmune thyroid diseases
  9. Role of regulatory T cells in pathogenesis and therapeutics of Graves’ disease and Graves’ orbitopathy
  10. Serum thyroid hormone-binding proteins
  11. Smoking and the thyroid
  12. Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors
  13. Regulatory T Cells in the Pathogenesis of Graves’ Disease
  14. Evaluation of the Safety of Neauvia Stimulate Injectable Product in Patients with Autoimmune Thyroid Diseases Based on Histopathological Examinations and Retrospective Analysis of Medical Records
  15. Editorial: Immunocellular mechanisms and endocrine organs
  16. Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves’ disease patients during methimazole treatment
  17. How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases?
  18. Clinical and oncological outcomes in single-stage versus staged surgery for pediatric craniopharyngiomas: a multicenter retrospective study
  19. A potential role of human RNASET2 overexpression in the pathogenesis of Graves’ disease
  20. The Old and the New in Subacute Thyroiditis: An Integrative Review
  21. Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
  22. Management of Graves’ hyperthyroidism: present and future
  23. SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review
  24. SARS-CoV-2 detection in primary thyroid sarcoma: coincidence or interaction?
  25. Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis
  26. Paraneoplastic hyperthyroidism in hCG-secreting metastatic testicular cancer
  27. Vitamin D, Chronic Migraine, and Extracranial Pain: Is There a Link? Data From an Observational Study
  28. Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression
  29. Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
  30. Predicting the Risk of Graves Disease Relapse: Commentary on “Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease”
  31. Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher
  32. Liraglutide is an effective drug for the treatment of obesity also in real life
  33. Negative impact of high body mass index on cetuximab-mediated cellular cytotoxicity against human colon carcinoma cells
  34. When primary hyperparathyroidism comes as good news
  35. Gastric Xanthomatous Hyperplastic Polyps – Just an Incidental Endoscopic Finding?
  36. Treatment of moderate-to-severe and active Graves’ orbitopathy: a step forward from the OPTIC study
  37. The interplay between thyroid and liver: implications for clinical practice
  38. Oral steroid prophylaxis for Graves’ orbitopathy after radioactive iodine treatment for Graves’ disease is not only effective, but also safe
  39. Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review
  40. Features and outcome of differentiated thyroid carcinoma associated with Graves’ disease: results of a large, retrospective, multicenter study
  41. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management
  42. Pre-operative evaluation of obese patients admitted for bariatric surgery: observations suggesting the introduction of a detailed screening for thyroid diseases
  43. Decreased levels of vitamin D may favor diabetes
  44. Vitamin D, visceral obesity and metabolic diseases
  45. Demographic and baseline characteristics of an obese population admitted for bariatric surgery in a secondary care centre
  46. Metabolic profile reversal after bariatric surgery
  47. Physical performance in newly diagnosed hypothyroidism: a pilot study
  48. The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study
  49. Masked hypertension in newly diagnosed hypothyroidism: a pilot study
  50. Outcome Prediction of Treatment of Graves’ Hyperthyroidism with Antithyroid Drugs
  51. Pituitary apoplexy during pregnancy: a rare, but dangerous headache
  52. Prevalence and Natural History of Graves' Orbitopathy in a Large Series of Patients With Newly Diagnosed Graves' Hyperthyroidism Seen at a Single Center